Myriad Genetics Was Informed On Friday, November 1, 2024, Of An Updated Medical Policy From UnitedHealthCare Restricting Access To Multi-Gene Panel Pharmacogenetic Tests, Including Myriad's Genesight Test, Under Its Commercial And Individual Exchange...
Myriad Genetics Was Informed On Friday, November 1, 2024, Of An Updated Medical Policy From UnitedHealthCare Restricting Access To Multi-Gene Panel Pharmacogenetic Tests, Including Myriad's Genesight Test, Under Its Commercial And Individual Exchange...
Myriad Genetics Was Informed On Friday, November 1, 2024, Of An Updated Medical Policy From UnitedHealthCare Restricting Access To Multi-Gene Panel Pharmacogenetic Tests, Including Myriad's Genesight Test, Under Its Commercial And Individual Exchange Benefit Plans, Effective January 1st, 2025
萬基遺傳公司於2024年11月1日星期五收到了UnitedHealthCare更新的醫療政策通知，限制了包括Myriad的GeneSight測試在內的多基因面板藥物基因檢測項目的接入，適用於其商業和個人交易所福利計劃，生效日期爲2025年1月1日。
Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1st, 2025.
萬基遺傳公司（納斯達克股票代碼:MYGN）是遺傳測試和精準醫學領域的領導者，於2024年11月1日星期五獲悉UnitedHealthcare發佈了一項更新的醫療政策，限制了多基因面板藥物基因檢測項目的接入，包括Myriad的GeneSight測試，在其商業和個人交易所福利計劃下生效日期爲2025年1月1日。
After initial review of the updated policy, the company strongly disagrees with UnitedHealthcare's inclusion of GeneSight in its decision to change its coverage policy of multi-gene panels based on its rationale that there is insufficient evidence of efficacy to support coverage of GeneSight. Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test, GeneSight, and is seeking to ensure that enrollees continue to have access to the test.
在初步審查更新的政策後，該公司強烈反對UnitedHealthcare將GeneSight納入更改其多基因面板覆蓋政策的決定，理由是缺乏支持GeneSight覆蓋的充分證據。萬基正在積極與UnitedHealthcare合作，討論支持萬基專有且臨床差異化的精神健康藥物檢測GeneSight的大量證據，並尋求確保參保人繼續可以接受該測試。
譯文內容由第三人軟體翻譯。
